C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development
China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...
Cancer
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...
Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy
Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Jacobio Pharma’s KRAS Inhibitor Glecirasib Advances to Pivotal Pancreatic Cancer Trial
China-based Jacobio Pharma (HKG: 1167) has announced that it has received the green light from...
Amoytop Biotech’s Pegfilgrastim (Y Shape) Approved for Marketing by NMPA
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical...
Helio Genomics’ Sister Company LAMH Wins NMPA Approval for Liver Cancer Test in China
Helio Genomics has announced that its ‘sister company’ Laboratory for Advanced Medicine & Health Group...
Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE
The China’s Center for Drug Evaluation (CDE) website has indicated that Huadong Medicine Co., Ltd...
Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC/GEJ Cancer Study
Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data...
InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection
InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...
Jiangsu Hengrui Medicine Gets NMPA Approval for HRS-4357 Clinical Study in Prostate Cancer
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...
Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Jacobio Pharma Reports Promising Clinical Results for KRAS G12C Inhibitor Gecirasib in CRC
China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor,...
Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment
China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor,...
WestGene Biopharma Secures $42 Million in Funding to Advance mRNA Therapeutics
Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round,...
Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...
Shandong Buchang Pharmaceuticals’ BC001 Gets Clinical Trial Approval for Solid Tumors
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical...